Wall Street brokerages expect Ocular Therapeutix Inc (NASDAQ:OCUL) to report ($0.36) earnings per share for the current quarter, Zacks reports. Three analysts have issued estimates for Ocular Therapeutix’s earnings, with estimates ranging from ($0.38) to ($0.33). Ocular Therapeutix reported earnings per share of ($0.44) during the same quarter last year, which would indicate a positive year over year growth rate of 18.2%. The company is scheduled to report its next quarterly earnings report on Thursday, March 14th.

According to Zacks, analysts expect that Ocular Therapeutix will report full year earnings of ($1.54) per share for the current financial year, with EPS estimates ranging from ($1.70) to ($1.47). For the next year, analysts anticipate that the business will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.50) to ($0.80). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Ocular Therapeutix.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.02). Ocular Therapeutix had a negative net margin of 2,822.15% and a negative return on equity of 133.73%. The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.45 million.

A number of equities research analysts recently issued reports on OCUL shares. Cantor Fitzgerald set a $22.00 target price on Ocular Therapeutix and gave the company a “buy” rating in a research report on Wednesday, October 3rd. BidaskClub raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Thursday, September 27th. JMP Securities reaffirmed a “buy” rating and set a $9.00 price target on shares of Ocular Therapeutix in a research report on Thursday, October 11th. Zacks Investment Research cut shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research report on Wednesday, July 25th. Finally, ValuEngine cut shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Friday, September 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Ocular Therapeutix has an average rating of “Buy” and a consensus price target of $11.45.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Teachers Advisors LLC lifted its position in shares of Ocular Therapeutix by 24.1% during the third quarter. Teachers Advisors LLC now owns 67,202 shares of the biopharmaceutical company’s stock worth $462,000 after purchasing an additional 13,061 shares in the last quarter. Man Group plc acquired a new position in shares of Ocular Therapeutix during the third quarter worth $3,461,000. Dimensional Fund Advisors LP acquired a new position in shares of Ocular Therapeutix during the third quarter worth $200,000. Trexquant Investment LP acquired a new position in shares of Ocular Therapeutix during the third quarter worth $139,000. Finally, BlackRock Inc. lifted its position in shares of Ocular Therapeutix by 16.6% during the third quarter. BlackRock Inc. now owns 2,292,263 shares of the biopharmaceutical company’s stock worth $15,770,000 after purchasing an additional 326,381 shares in the last quarter. 52.15% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix stock traded up $0.12 during midday trading on Friday, reaching $5.23. The stock had a trading volume of 4,932 shares, compared to its average volume of 412,681. Ocular Therapeutix has a 1-year low of $3.30 and a 1-year high of $8.28. The firm has a market cap of $215.34 million, a PE ratio of -2.36 and a beta of 1.55. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.34 and a current ratio of 4.35.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

Featured Article: Average Daily Trade Volume – ADTV

Get a free copy of the Zacks research report on Ocular Therapeutix (OCUL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.